Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855236 | 0.83 | CACNA1I (0.38) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL20457815 | 0.80 | CACNA1I (0.36) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL2693246 | 0.80 | PDE2A (0.36) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL20228078 | 0.80 | CACNA1I (0.36) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL14946753 | 0.80 | CACNA1I (0.42) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL24636032 | 0.80 | CACNA1I (0.36) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL14946815 | 0.78 | LMNA (0.38) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL12724966 | 0.78 | ALOX5AP (0.36) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL25884709 | 0.77 | CACNA1I (0.35) | CACNA1ITSHRKIF11LMNATYR | |
| SCHEMBL12915235 | 0.76 | TSHR (0.33) | CACNA1ITSHRKIF11LMNATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | CACNA1I 15/4885TSHR 2889/4885KIF11 3602/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | CACNA1I 15/4885TSHR 2889/4885KIF11 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.